Regulatory approval to Entod Pharma for PresVu, meant to treat presbyopia, was revoked as the firm marketed it as a ...

Mumbai-based Entod Pharmaceuticals said on Thursday that it has decided to move the court to challenge the national drug regulator’s suspension of permission to manufacture and market its pilocarpine ...

According to the suspension order copy accessed by News18, the company had received approval for PresVu Pilocarpine Hydrochloride Ophthalmic Solution USP 1.25 per cent, but some of the promotional ...

On September 4, the drug regulator had asked for an explanation from the company for the claims it made in the press following which the drug-maker also submitted its response.

The Drugs Controller General of India (DCGI) stated in an order dated September 10 that the Directorate had approved on August 20 for the production and distribution of Pilocarpine Hydrochloride ...

In response to the various alleged misleading claims made by Entod Pharma in respect to its Opthalmologic product, Drugs ...

The Drug Controller General of India has suspended the manufacturing licence of PresVu eye drops Read on to know why it was suspended ...

Entod Pharma to challenge DCGI's suspension of permission for PresVu in court: Our Bureau, New Delhi Thursday, September 12, 2024, 13:45 Hrs [IST] Entod Pharmaceuticals announced ...

The Directorate General of Health Services (DGHS), under the Central Drugs Standard Control Organisation (CDSCO), has ...

Entod Pharmaceuticals denies making false claims about their new PresVu eye drops and plans to challenge the suspension by ...

The company, which was aiming for an October launch in the Indian market, said that it will challenge the suspension in court ...

DCGI suspends Entod Pharma`s eye drop permission for presbyopia treatment due to unapproved claims. The company will ...